AUA Guidelines: Medical & Surgical Management of Kidney and Ureteral Stones

Advances in Prostate Stents Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Ricardo R. Gonzalez, MD

AUA Guidelines: Medical & Surgical Management of Kidney and Ureteral Stones Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kevin Koo, MD, MPH, MPhil To access the full Medical Management of Kidney Stones guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/medical-management-of-kidney-stones To access the full Surgical Management of Kidney and Ureteral Stones guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/surgical-management-of-kidney-and-ureteral-stones

Update Series (2026) Lesson 27: Case-Based Discussion of the Male Chronic Pelvic Pain Guideline Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

Core Curriculum: Pediatric Oncology Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Amanda F. Buchanan, MD AUA Urology Core Curriculum: https://cme.auanet.org/Page/Core-Curriculum Outline: Segment 1: Renal Masses in Children 12y Segment 3: Testicular GCT Segment 4: Bladder/Prostate RMS Segment 5: Paratestis RMS

Starting HoLEP without Fellowship Training Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Daniel S. Kellner, MD

AUA Guidelines: Vasectomy Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Richard Lee, MD, MBA To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/vasectomy-guideline

Microultrasound for the Detection of Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Christian P. Pavlovich, MD

AUA Guidelines: Non-Muscle Invasive Bladder Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Peter E. Clark, MD and Jeffrey M. Holzbeierlein, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.

Update Series (2026): Evaluating Abnormal Urine Cytology Without Clinically Demonstrable Urinary Tract Disease Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Sherri M. Donat, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Advanced Prostate Cancer in the News 2026: A Case-Based Multidisciplinary Update CME Available: https://cme.auanet.org/URL/26DC010ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral androgen blockers/inhibitors. Furthermore, to recognize high volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. In addition, to recognize and employ molecular genetic testing to help dictate proper therapy. 2. Non Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): Diagnose M0CRPC and to be able to educate patients about using novel oral androgen receptor targeted agents added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three novel oral agents and to educate patients about side-effects and toxicities. Finally, to understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate Resistant Prostate Cancer (M1 CRPC): Define and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and to be able to educate their patients on treatment options and be able to participate in a multidisciplinary team caring for men with this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with an ever changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Describe the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, Immune Checkpoint agents and novel AR targeted agents emerging in 2026 and beyond. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc